7/8/2024 The National Medical Products Administration has approved 2 innovative products, which originate from FARAPULSE, Inc.,
a subsidiary of Boston Scientific, namely the "Disposable Cardiac Pulsed Electric Field Ablation Catheter" and the "Cardiac Pulsed Electric Field Ablation System".
It is reported that as the world's first approved pulsed electric field ablation (PFA) product in the field of arrhythmia, it has previously been approved in Europe
and United States, and has treated more than 70,000 patients worldwide so far. In addition to the first-generation PFA ablation technology, Farapulse, Poco will
also launch the FARAWAVE Nav ablation catheter with magnetic positioning and the FARAVIEW software module this year.
Ablation is a medical procedure used to destroy abnormal tissues and is widely used in the treatment of heart disease, cancer, and other diseases.
The current ablation market covers a variety of technologies, including pulsed ablation, thermal ablation (radiofrequency, microwave, laser, etc.), and cold ablation.
With the advancement of medical technology and the increasing demand for disease treatment, the ablation market is experiencing rapid growth. According to
Mordor Intelligence, the global ablation market was valued at $4.6 billion in 2023 and is expected to reach $7.8 billion by 2028, growing at a compound annual
growth rate (CAGR) of 10.7%.
In the current ablation market, thermal ablation technology occupies half of the market due to its mature technical system and wide range of application scenarios,
but in the face of precise control and thermal damage risks, the industry is actively exploring more refined solutions. At the same time, pulse ablation
and cold ablation technologies have a smaller market share, but they are catching up at a faster growth rate, especially in the pursuit of minimizing tissue damage
and improving treatment accuracy.
Pulsed ablation
The dual driving force of technological innovation and application expansion
Pulse ablation technology is in the golden age of rapid development, and the driving force behind it comes from the continuous innovation of technology and the
continuous expansion of application fields. In the field of cardiology, pulse ablation technology is gradually becoming the preferred treatment option due to its
breakthrough in precision and indication range. The global PFA market is forecast to grow from approximately $130 million in 2023 to approximately $1.17 billion
by 2033, at a compound annual growth rate (CAGR) of 24.2%.
Earlier in July this year, CardiPulse®, the first petal-shaped pulsed electric field ablation system with completely independent intellectual property rights on the market in China, completed the first batch of applications
after listing in the First Affiliated Hospital of Harbin Medical University, Suzhou Municipal Hospital, Wuhan Central Hospital, Jingzhou First People's Hospital, Ruikang
Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University, and other well-known
medical centers in China, and won unanimous praise.
Radiofrequency ablation
Continuous evolution and challenges of mature technologies
Radiofrequency ablation technology, as the main force in the ablation market, although the technology is quite mature, but in the face of precise control problems
and potential thermal damage risks, the industry is actively seeking more sophisticated solutions. As a global leader in radiofrequency ablation, Johnson & Johnson
has demonstrated high achievements in the research and development of mapping systems and related consumables. At present, there are three mainstream 3D
mapping systems in the world, and Johnson & Johnson's Carto system is one of them, which has been on the market for many years and still firmly occupies the
world's major markets.
Cold ablation
The unique advantages and broad prospects of cryogenic operation
Cryoablation is the process of evaporation of the liquid refrigerant in the balloon to absorb heat, so that the temperature around the ablation target is abruptly
reduced, and the abnormal cardiomyocytes in the area are damaged or killed through low temperature. Although the current market share of cold ablation
technology is relatively small, the unique advantages of cryogenic operation make it popular in scenarios where minimal tissue damage is pursued. As of
July 2024, more than 200,000 cases of cryoablation of atrial fibrillation have been performed in China.
In summary, ablation technology is in an era of vitality and innovation. Whether it is FARAPULSE, Inc.'s pulsed electric field ablation technology, or Antek Medical's
cryoablation device, they have demonstrated excellent technical strength and market potential in their respective fields. With the continuous advancement of
technology and the continuous growth of market demand, ablation technology has not only deepened its application in the existing field, but also shown great
potential in exploring unknown fields, indicating that it will play a more important role in future medical practice, providing patients with safer and more effective
treatment options, and leading medical technology to a new peak.
